Onbrez Breezhaler · DIN 02376938 · 75 mcg · Inh Pd-capsule
Limited Use, Reason for Use code 443 required; Health Canada lists this DIN as Cancelled post market since 2023-05-12 — choose a marketed DIN from the same-category list.Discontinued May 12, 2023 · checked November 18, 2026
StatusLimited Use, Reason for Use code 443 required; Health Canada lists this DIN as Cancelled post market since 2023-05-12 — choose a marketed DIN from the same-category list.
Write on scriptReason for Use code 443 (criteria below); Health Canada lists this DIN as Cancelled post market since 2023-05-12 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 443
Reason for Use code 443
For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.
Note: The dose of Onbrez Breezhaler should not exceed 75mcg per day.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Onbrez Breezhaler · DIN 02376938
Manufacturer: Novartis Pharma Canada Inc.; listing date 2013-04-30
Health Canada: Cancelled post market since 2023-05-12 · brand ONBREZ BREEZHALER · ATC R03AC18 INDACATEROL · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL MALEATE) 75 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Onbrez Breezhaler: Formulary list price $1.55 per unit (the source does not state the unit; exact figure $1.5500). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02376938)
Source record
DIN 02376938: Onbrez Breezhaler
Raw flags: sec12=Y, sec3=Y
Item: 121200104; group id 228; item number 0407; lccId 00231; manufacturer id NOV
Source form: Inh Pd-Cap; strength: 75mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.5500; ministry $1.5500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02376938
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86250
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since May 12, 2023 — choose a marketed DIN from the same-category list.